Last month we met with Professors Jeffrey Goldberg and Joyce Liao of Stanford University. The road to treatment for Autosomal Dominant Optic Atrophy (ADOA)

During our ADOA day on Saturday, November 1, 2025, Aishwarya Kundu, Senior Director of Translational Research, shared the latest PYC results. You can read them in this issue.

This time we share an extra special blog post from Dr. Steve Gross, who is working at Stoke Therapeutics on the development of a promising new drug

Promising research into ADOA(-plus) and mitochondria In previous posts on the road to treatment, we have mainly highlighted research in the United States. But also in

New Developments in ADOA Research: ASHA Therapeutics' Approach to Slow and Partially Reverse ADOA by Peter Makai End of April

Restoring Vision: A Breakthrough in Retinal Cell Therapy Autosomal Dominant Optic Atrophy (ADOA) is a genetic disorder that primarily affects the optic nerves. The optic nerves are

The Impact of ADOA – Interview with Christina Eckmann-Hansen In October we spoke with Christina Eckmann-Hansen, an optometrist who did a PhD research on ADOA at

New Developments in Optic Nerve Regeneration – Interview with Petr Baranov We had an interview with Dr. Petr Baranov, a researcher at

PYC: first patient to receive ADOA medication in October 2024 At the end of September we had a joint meeting with PYC and the Autosomal Dominant Optic Atrophy Association,

How do clinical trials work at ADOA? Right now, several companies are about to start clinical trials (PYC, Stoke, etc.). These are

Taking stock of Idebenone By Peter Makai PhD and Christina Barckhausen PhD Idebenone is a licensed drug for the disease Leber hereditary optic neuropathy

The Road to Treatment 23 Interview with Tom Schwarz from Harvard We contacted Thomas Schwarz, who is a Professor of Neurobiology at Harvard Medical